The "business" behind the hospital involved in the abortion of a pregnant woman in Xi'an: the stock price fell sharply

　　China-Singapore Jingwei, January 6th (Lin Wansi, Wang Yuling) Under the epidemic, Xi'an, which was closed in the city, caused widespread concern in the society due to an abortion of pregnant and lying-in women, causing severe social impact.

　　On the afternoon of January 6, the Xi'an Municipal Government held a press conference on the prevention and control of the new crown pneumonia epidemic in Xi'an (the 48th session).

At the meeting, Liu Shunzhi, director of the Xi'an Health and Health Commission, apologized on behalf of the Xi'an Health and Health Commission for the miscarriage of pregnant women in Xi'an High-tech Zone.

　　Prior to this, on January 5, experts from Shaanxi Province and Xi'an Municipal Health Commission organized an investigation and determined that the incident was a responsible accident.

　　Subsequently, Xi'an High-tech Hospital has dealt with the relevant persons in charge: Fan Yuhui, general manager of Xi'an High-tech Hospital, was suspended, and relevant persons in charge of the outpatient department and medical department were removed from their posts.

　　What is the capital quality behind Xi'an High-tech Hospital, which has attracted attention due to maternal abortion incidents?

　　On January 6, the share price of International Medical, the parent company of Xi'an High-tech Hospital, fell sharply.

The data shows that as of the noon closing, the international medical stock price was reported at 9.85 yuan per share, corresponding to a decline of 8.8%.

After midday, International Medical's stock price rebounded, and finally closed at 10.28 yuan per share, a 4.81% drop.

　　Image source: Official website of Shaanxi Provincial Health and Construction Commission

　　According to the 2021 semi-annual report of International Medicine, it currently operates medical institutions such as Xi’an International Medical High-tech Hospital, Xi’an International Medical Center Hospital, and Xi’an International Medical Shangluo Hospital.

　　According to the official website of Xi'an Health Commission, in 2011, the nature of the operation of Xi'an High-tech Hospital changed from non-profit to profit.

Sino-Singapore Jingwei noted that, among the total number of patients admitted to international medicine, a single hospital in Xi'an High-tech Hospital accounts for more than 50%.

　　According to the 2021 semi-annual report of International Medicine, in the first half of 2021, the number of outpatient and emergency visits of International Medicine was 1.0285 million, and the number of hospitalizations was 57,600.

Among them, the total number of outpatient and emergency department of Xi'an High-tech Hospital exceeded 650,000, accounting for over 63% of the international medical outpatient and emergency department, and the number of inpatients exceeded 24,000, accounting for over 41%.

　　In terms of revenue, Xi'an High-tech Hospital is also the "main force" of international medical revenue.

According to the 2020 annual report of the International Medicine, the 2020 operating income of the International Medicine is 1.607 billion yuan, and the net profit attributable to the parent is 45.36 million yuan.

Among them, Xi'an High-tech Hospital's 2020 revenue reached 799 million yuan, accounting for 49.72% of the total international medical revenue.

　　After the trading on September 16, 2021, Liu Jianshen, the actual controller of International Medicine, issued a proposal to all employees of the company to increase the company’s stock holdings. The announcement stated that anyone who bought the company during the period from September 17 to October 11, 2021 For employees who hold stocks for more than 12 months and are employed, Liu Jianshen will compensate for the losses incurred by increasing the company’s stock holdings during the aforementioned time period, and the employees will retain their stock appreciation gains.

　　Affected by this "underweight increase", on September 17, the company's stock price rose by 9.97% daily, closing at 11.03 yuan per share.

To this end, the Shenzhen Stock Exchange issued a letter of concern.

　　According to the 2021 third quarter report of International Medicine, in the first three quarters of 2021, International Medicine realized operating income of 2.049 billion yuan, an increase of 91.04% year-on-year, and the net profit loss attributable to shareholders of listed companies was 585 million yuan, a year-on-year decrease of 17.36%.

Among them, the net profit loss attributable to shareholders of listed companies in the third quarter of International Medicine was about 225 million yuan, a year-on-year decrease of 45.78%.

(Zhongxin Jingwei APP)

All rights reserved by Sino-Singapore Jingwei. Without written authorization, no unit or individual may reprint, extract or use it in other ways.